Olieni (Olaparib) tablets On September 1, 2021, Olieni (Olaparib) tablets developed and produced by ASEAN Pharmaceutical were approved for marketing by FDD.

Olieni (Olaparib) is a PARP (poly ADP-ribose polymerase) inhibitor. Olieni is currently the only PARP inhibitor that can significantly improve the overall survival (OS) of BRCA-mutated mCRPC patients compared with new hormone therapy (NHT). Olieni kills tumor cells by inhibiting PARP enzyme activity and preventing PARP from dissociating from DNA, synergizing DNA damage repair function defects. Whether used as a monotherapy or in combination with platinum-based chemotherapy, it can inhibit the growth of tumor cells in test tubes, thereby reducing the growth of human tumors.

Olieni (Olaparib) has been approved for ovarian cancer, pancreatic cancer, breast cancer, and prostate cancer.

The Lao ASEAN Pharmaceutical version of Olaparib is available in two dosage forms: capsules and tablets. Among them, the specifications of Olaparib capsules are 50mg*112 capsules/bottle, while the specifications of Olaparib tablets are two, namely 100mg*60 tablets/bottle and 150mg*60 tablets/bottle.